A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1914-1922

  Daftarian, Pirouz M ^a,b,c   Stone, Geoffrey W ^c   Kovalski, Leticia ^b   Kumar, Manoj ^b   Vosoughi, Aram ^b   Urbieta, Maitee ^a   Blackwelder, Pat ^d   Dikici, Emre ^b   Serafini, Paolo ^c   Duffort, Stephanie ^a   Boodoo, Richard ^c   Rodríguez Cortés, Alhelí ^e   Lemmon, Vance ^d   Deo, Sapna ^b   Alberola, Jordi ^e   Perez, Victor L ^a   Daunert, Sylvia ^b   Ager, Arba L ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Biochemistry and Molecular Biology ^*  (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Adoptive immunity; Immunochemotherapy; Intracellular; Leishmaniasis; Nanocarrier; Obligate intracellular parasites; Vaccine

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DENDRIMER; EPITOPE; NANOCARRIER; PAN DR BINDING EPITOPE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BYSTANDER EFFECT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPOTENTIATION; IN VIVO STUDY; LEISHMANIA MAJOR; LOW DRUG DOSE; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; SKIN LEISHMANIASIS; T LYMPHOCYTE;

ADOPTIVE IMMUNITY; IMMUNOCHEMOTHERAPY; INTRACELLULAR; LEISHMANIASIS; NANOCARRIER; OBLIGATE INTRACELLULAR PARASITES; VACCINE;

ADAPTIVE IMMUNITY; AMPHOTERICIN B; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIPROTOZOAL AGENTS; DENDRIMERS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EPITOPES; FEMALE; INJECTIONS, INTRAPERITONEAL; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES;

EID: 84888597707     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit378     Document Type: Article

References (28)

1. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial. Lancet 2011; 377:477-86.
2. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-12.
3. Murray HW. Leishmaniasis in the United States: Treatment in 2012. Am J Trop Med Hyg 2012; 86:434-40.
4. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011; 25: 973-7.
5. Rapp C, Imbert P, Darie H, et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate. Bull Soc Pathol Exot 2003; 96:209-11.
6. Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:1028-33.
7. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007; 2:16.
8. Daftarian P, Kaifer AE, Li W, et al. Peptide-conjugated PAMAM dendrimer as a universal platform for antigen presenting cell targeting and effective DNA-based vaccinations. Cancer Res 2011; 71: 7452-62.
9. Daftarian P, Sharan R, HaqW, et al. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 2005; 23:3453-68.
10. La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus- CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012; 205:1294-304.
11. Alexander J, del Guercio MF, Maewal A, et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 2000; 164:1625-33.
12. Belot F, Guerreiro C, Baleux F, Mulard LA. Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection. Chemistry 2005; 11:1625-35.
13. Hung C-F, Tsai Y-C, He L, Wu TC. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther 2007; 15:1211-9.
14. Wan Y, Yuan S, Xue X, et al. The preventive effect of adjuvant-free administration of TNF-PADRE autovaccine on collagen-II-induced rheumatoid arthritis in mice. Cell Immunol 2009; 258:72-7.
15. Okwor I, Mou Z, Liu D, Uzonna J. Protective immunity and vaccination against cutaneous leishmaniasis. Front Immunol 2012; 3:128.
16. Medina SH, El-Sayed MEH. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009; 109:3141-57.
17. Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L, et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 2007; 25:7962-71.
18. Bretagne S, Durand R, Olivi M, et al. Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol 2001; 8:828-31.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8.
20. Olbrich AR, Schimmer S, Dittmer U. Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J Virol 2003; 77:10658-62.
21. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpGDNA- mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000; 165:1228-35.
22. Olishevsky S, Shlyakhovenko V, Kozak V, Yanish Y. Response of different organs of immune system of mice upon administration bacterial CpG DNA. Exp Oncol 2005; 27:290-7.
23. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008; 26:1709-24.
24. Brandonisio O, Spinelli R, Pepe M. Dendritic cells in Leishmania infection. Microbes Infect 2004; 6:1402-9.
25. Das A, Ali N. Vaccine Development against Leishmania donovani. Front Immunol 2012; 3:99.
26. Antoine JC, Jouanne C, Lang T, Prina E, Chastellier C, Frehel C. Localization of major histocompatibility complex class II molecules in phagolysosomes of murine macrophages infected with Leishmania amazonensis. Infect Immun 1991; 59:764-75.
27. Antoine JC, Lang T, Prina E, Courret N, Hellio R. H-2M molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of Leishmania-infected macrophages and internalized by amastigotes of L. amazonensis and L. mexicana. J Cell Sci 1999; 112(Pt 15):2559-70.
28. Prina E, Jouanne C, de Souza Lao S, Szabo A, Guillet JG, Antoine JC. Antigen presentation capacity of murine macrophages infected with Leishmania amazonensis amastigotes. J Immunol 1993; 151:2050-61.